Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Production of New Life Naturals: For Her Senses™ supplement to begin immediately
Apr 24, 2012, 08:30 ET
FORT LAUDERDALE, Fla., April 24, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, soon to be changed from Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that it has contracted with an FDA-approved manufacturer to begin production of the first supplement in its New Life Naturals™ product line.
The new supplement – New Life Naturals: For Her Senses™ – is an all-natural product intended to help the nearly 48% of American women suffering with female sexual dysfunction (FSD). Nouveau Life Pharmaceuticals began work on the supplement's formulation in February of this year and finalized the formula ahead of schedule.
In order to minimize time-to-market and begin production immediately, Nouveau Life opted to partner with an FDA-approved manufacturing facility based in the U.S. The facility is a cGMP (current good manufacturing practice) compliant facility and meets all FDA requirements to manufacture food supplements and over the counter pharmaceuticals.
Nouveau Life expects production of the For Her Senses™ supplement to begin in the coming days and anticipates the nutraceutical will be available for sale to the public within two weeks.
About Hybrid Fuels, Inc.
The company was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.
Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.
CONTACT:
Nouveau Life Pharmaceuticals, Inc. - 954-903-2993
SOURCE Nouveau Life Pharmaceuticals, Inc.